![Actinium Pharmaceuticals, Inc. logo](/logos/ATNM.webp)
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Overview | Financials
Company Name | Actinium Pharmaceuticals, Inc. |
Symbol | ATNM |
Currency | USD |
Price | 4.49 |
Market Cap | 121,219,224 |
Dividend Yield | 0% |
52-week-range | 4.3 - 14.7 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sandesh C. Seth M.B.A., M.S., MBA |
Website | https://www.actiniumpharma.com |
An error occurred while fetching data.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD